Italy reconvenes CUD medical devices commission
This article was originally published in Clinica
Italy has reconvened, until July 2010, the medical devices commission (CUD). The February 7 decree establishing its second renewal since 2002 has not changed its remit since taking on the "advisory" roles imposed in its first renewal in 2005. These feature the initiatives launched in 2007 to reclassify the devices available for use by the national health system (SSN), against new reference prices (see Clinica No 1286, p 3). The CUD's core competencies are to direct all national healthcare technology assessment, market regulation, product registration, surveillance and quality R&D activities.
You may also be interested in...
AMAG outlines plans for retrospective real-world evidence studies, and possibly a new placebo-controlled trial with a primary endpoint of preterm birth <32 weeks, in a filing opposing the Center for Drug Evaluation and Research’s proposal to withdraw the drug.
The leading Korean pharma firm’s oral, third-generation EGFR-TKI is approved in the country, providing a new option for patients with advanced NSCLC and increasing hopes for global approvals given an ongoing global Phase III combination trial led by partner J&J.
DePuy Synthes expects its Velys robotic-assisted system to be cost-effective, easy-to-use and to be well-suited for use in ambulatory surgery centers.